

Audit Review Table				
Molina Healthcare of New Mexico (Org ID: 955, SubID: 4112, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2018; Date & Timestamp - 6/25/2019 11:47:32 AM				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Effectiveness of Care: Prevention and				
Adult BMI Assessment (aba)		71.05%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)				
<i>BMI Percentile</i>		56.93%	R	Reportable
<i>Counseling for Nutrition</i>		46.23%	R	Reportable
<i>Counseling for Physical Activity</i>		40.88%	R	Reportable
Childhood Immunization Status (cis)				
<i>DTaP</i>		71.53%	R	Reportable
<i>IPV</i>		88.81%	R	Reportable
<i>MMR</i>		85.89%	R	Reportable
<i>H1B</i>		86.86%	R	Reportable
<i>Hepatitis B</i>		89.54%	R	Reportable
<i>VZV</i>		85.64%	R	Reportable
<i>Pneumococcal Conjugate</i>		72.02%	R	Reportable
<i>Hepatitis A</i>		83.70%	R	Reportable
<i>Rotavirus</i>		72.26%	R	Reportable
<i>Influenza</i>		45.50%	R	Reportable
<i>Combination #2</i>		69.34%	R	Reportable
<i>Combination #3</i>		65.21%	R	Reportable
<i>Combination #4</i>		64.23%	R	Reportable
<i>Combination #5</i>		57.91%	R	Reportable
<i>Combination #6</i>		38.44%	R	Reportable
<i>Combination #7</i>		57.18%	R	Reportable
<i>Combination #8</i>		38.44%	R	Reportable
<i>Combination #9</i>		34.55%	R	Reportable
<i>Combination #10</i>		34.55%	R	Reportable
Immunizations for Adolescents (ima)				
<i>Meningococcal</i>		75.91%	R	Reportable
<i>Tdap</i>		87.35%	R	Reportable
<i>HPV</i>		34.06%	R	Reportable
<i>Combination #1</i>		74.45%	R	Reportable
<i>Combination #2</i>		32.60%	R	Reportable
Lead Screening in Children (lsc)		42.29%	R	Reportable
Breast Cancer Screening (bcs)		55.54%	R	Reportable
Cervical Cancer Screening (ccs)		55.72%	R	Reportable
Chlamydia Screening in Women (chl)				
<i>16-20 Years</i>		50.95%	R	Reportable
<i>21-24 Years</i>		58.91%	R	Reportable
<i>Total</i>		54.34%	R	Reportable
Effectiveness of Care: Respiratory				
Appropriate Testing for Children with Pharyngitis (cwp)	Y	69.10%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)		24.12%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y			
<i>Systemic Corticosteroid</i>		67.62%	R	Reportable
<i>Bronchodilator</i>		79.37%	R	Reportable
Medication Management for People With Asthma (mma)	Y			
<i>5-11 Years: Medication Compliance 50%</i>		57.95%	R	Reportable
<i>5-11 Years: Medication Compliance 75%</i>		30.58%	R	Reportable
<i>12-18 Years: Medication Compliance 50%</i>		54.97%	R	Reportable
<i>12-18 Years: Medication Compliance 75%</i>		29.27%	R	Reportable
<i>19-50 Years: Medication Compliance 50%</i>		59.89%	R	Reportable
<i>19-50 Years: Medication Compliance 75%</i>		37.21%	R	Reportable
<i>51-64 Years: Medication Compliance 50%</i>		67.86%	R	Reportable
<i>51-64 Years: Medication Compliance 75%</i>		41.52%	R	Reportable
<i>Total: Medication Compliance 50%</i>		58.82%	R	Reportable
<i>Total: Medication Compliance 75%</i>		33.33%	R	Reportable

Asthma Medication Ratio (amr)	Y			
5-11 Years		73.10%	R	Reportable
12-18 Years		59.19%	R	Reportable
19-50 Years		45.91%	R	Reportable
51-64 Years		53.97%	R	Reportable
Total		58.45%	R	Reportable
Effectiveness of Care: Cardiovascular				
Controlling High Blood Pressure (cbp)		46.47%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	75.27%	R	Reportable
Statin Therapy for Patients With Cardiovascular Disease (spc)	Y			
Received Statin Therapy: 21-75 Years (Male)		76.95%	R	Reportable
Statin Adherence 80%: 21-75 Years (Male)		60.79%	R	Reportable
Received Statin Therapy: 40-75 Years (Female)		68.09%	R	Reportable
Statin Adherence 80%: 40-75 Years (Female)		63.75%	R	Reportable
Received Statin Therapy: Total		73.02%	R	Reportable
Statin Adherence 80%: Total		62.02%	R	Reportable
Effectiveness of Care: Diabetes				
Comprehensive Diabetes Care (cdc)				
Hemoglobin A1c (HbA1c) Testing		86.86%	R	Reportable
HbA1c Poor Control (>9.0%)		48.18%	R	Reportable
HbA1c Control (<8.0%)		42.09%	R	Reportable
HbA1c Control (<7.0%)			NQ	Not Required
Eye Exam (Retinal) Performed		62.77%	R	Reportable
Medical Attention for Nephropathy		89.78%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)		58.39%	R	Reportable
Statin Therapy for Patients With Diabetes (spd)	Y			
Received Statin Therapy		54.87%	R	Reportable
Statin Adherence 80%		59.12%	R	Reportable
Effectiveness of Care: Musculoskeletal				
Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	78.49%	R	Reportable
Effectiveness of Care: Behavioral				
Antidepressant Medication Management (amm)	Y			
Effective Acute Phase Treatment		49.62%	R	Reportable
Effective Continuation Phase Treatment		32.34%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y			
Initiation Phase		57.89%	R	Reportable
Continuation and Maintenance (C&M) Phase		74.01%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Y			
6-17 years - 30-Day Follow-Up		75.84%	R	Reportable
6-17 years - 7-Day Follow-Up		46.91%	R	Reportable
18-64 years - 30-Day Follow-Up		55.17%	R	Reportable
18-64 years - 7-Day Follow-Up		33.33%	R	Reportable
65+ years - 30-Day Follow-Up		50.00%	NA	Small Denominator
65+ years - 7-Day Follow-Up		50.00%	NA	Small Denominator
Total - 30-Day Follow-Up		60.94%	R	Reportable
Total - 7-Day Follow-Up		37.14%	R	Reportable
Follow-Up After Emergency Department Visit for Mental Illness (fum)	Y			
6-17 years - 30-Day Follow-Up		63.81%	R	Reportable
6-17 years - 7-Day Follow-Up		42.54%	R	Reportable
18-64 years - 30-Day Follow-Up		44.38%	R	Reportable
18-64 years - 7-Day Follow-Up		31.19%	R	Reportable
65+ years - 30-Day Follow-Up		0.00%	NA	Small Denominator
65+ years - 7-Day Follow-Up		0.00%	NA	Small Denominator
Total - 30-Day Follow-Up		50.34%	R	Reportable
Total - 7-Day Follow-Up		34.66%	R	Reportable
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (fua)	Y			
30-Day Follow-Up: 13-17 Years		8.93%	R	Reportable
7-Day Follow-Up: 13-17 Years		4.46%	R	Reportable
30-Day Follow-Up: 18+ Years		14.15%	R	Reportable
7-Day Follow-Up: 18+ Years		7.26%	R	Reportable
30-Day Follow-Up: Total		13.90%	R	Reportable
7-Day Follow-Up: Total		7.12%	R	Reportable

Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	79.85%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)		55.03%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)		82.61%	NA	Small Denominator
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	55.91%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y			
1-5 Years		10.00%	NA	Small Denominator
6-11 Years		28.72%	R	Reportable
12-17 Years		34.59%	R	Reportable
Total		32.25%	R	Reportable
Effectiveness of Care: Medication				
Annual Monitoring for Patients on Persistent Medications (mpm)	Y			
ACE Inhibitors or ARBs		83.70%	R	Reportable
Diuretics		85.57%	R	Reportable
Total		84.35%	R	Reportable
Effectiveness of Care:				
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)		1.08%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	87.91%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	27.65%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)		68.59%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y			
1-5 Years		0.00%	NA	Small Denominator
6-11 Years		0.93%	R	Reportable
12-17 Years		0.52%	R	Reportable
Total		0.66%	R	Reportable
Use of Opioids at High Dosage (uod)	Y	1.44%	R	Reportable
Use of Opioids From Multiple Providers (uop)	Y			
Multiple Prescribers		16.29%	R	Reportable
Multiple Pharmacies		3.97%	R	Reportable
Multiple Prescribers and Multiple Pharmacies		1.88%	R	Reportable
Risk of Continued Opioid Use (cou)	Y			
18-64 years - >=15 Days covered		8.84%	R	Reportable
18-64 years - >=31 Days covered		3.39%	R	Reportable
65+ years - >=15 Days covered		30.00%	NA	Small Denominator
65+ years - >=31 Days covered		0.00%	NA	Small Denominator
Total - >=15 Days covered		8.85%	R	Reportable
Total - >=31 Days covered		3.39%	R	Reportable
Access/Availability of Care				
Adults' Access to Preventive/Ambulatory Health Services (aap)				
20-44 Years		73.20%	R	Reportable
45-64 Years		80.21%	R	Reportable
65+ Years		33.25%	R	Reportable
Total		75.26%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)				
12-24 Months		97.12%	R	Reportable
25 Months - 6 Years		88.68%	R	Reportable
7-11 Years		91.33%	R	Reportable
12-19 Years		90.93%	R	Reportable
Annual Dental Visit (adv)	Y			
2-3 Years		63.64%	R	Reportable
4-6 Years		79.27%	R	Reportable
7-10 Years		81.87%	R	Reportable
11-14 Years		78.28%	R	Reportable

15-18 Years		69.93%	R	Reportable
19-20 Years		51.86%	R	Reportable
Total		74.61%	R	Reportable
Initiation and Engagement of AOD Abuse or Dependence Treatment (iet)	Y			
Alcohol abuse or dependence: Initiation of AOD Treatment: 13-17 Years		41.51%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: 13-17 Years		3.77%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: 13-17 Years		41.67%	NA	Small Denominator
Opioid abuse or dependence: Engagement of AOD Treatment: 13-17 Years		0.00%	NA	Small Denominator
Other drug abuse or dependence: Initiation of AOD Treatment: 13-17 Years		49.30%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: 13-17 Years		15.04%	R	Reportable
Total: Initiation of AOD Treatment: 13-17 Years		45.45%	R	Reportable
Total: Engagement of AOD Treatment: 13-17 Years		13.05%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment: 18+ Years		36.00%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: 18+ Years		12.05%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: 18+ Years		61.83%	R	Reportable
Opioid abuse or dependence: Engagement of AOD Treatment: 18+ Years		32.73%	R	Reportable
Other drug abuse or dependence: Initiation of AOD Treatment: 18+ Years		40.63%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: 18+ Years		10.47%	R	Reportable
Total: Initiation of AOD Treatment: 18+ Years		41.78%	R	Reportable
Total: Engagement of AOD Treatment: 18+ Years		15.25%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment: Total		36.19%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: Total		11.76%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: Total		61.64%	R	Reportable
Opioid abuse or dependence: Engagement of AOD Treatment: Total		32.42%	R	Reportable
Other drug abuse or dependence: Initiation of AOD Treatment: Total		41.56%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: Total		10.95%	R	Reportable
Total: Initiation of AOD Treatment: Total		42.01%	R	Reportable
Total: Engagement of AOD Treatment: Total		15.12%	R	Reportable
Prenatal and Postpartum Care (ppc)				
Timeliness of Prenatal Care		75.43%	R	Reportable
Postpartum Care		59.85%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	Y			
1-5 Years		14.29%	NA	Small Denominator
6-11 Years		66.39%	R	Reportable
12-17 Years		61.66%	R	Reportable
Total		62.27%	R	Reportable
Utilization				
Well-Child Visits in the First 15 Months of Life (w15)				
0 Visits		1.22%	R	Reportable
1 Visit		1.46%	R	Reportable
2 Visits		3.65%	R	Reportable
3 Visits		3.65%	R	Reportable
4 Visits		8.52%	R	Reportable
5 Visits		17.27%	R	Reportable
6+ Visits		64.23%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)		62.77%	R	Reportable
Adolescent Well-Care Visits (awc)		49.88%	R	Reportable
Frequency of Selected Procedures (fsp)			R	Reportable
Ambulatory Care: Total (amba)			R	Reportable

Ambulatory Care: Dual Eligibles (ambb)			NQ	Not Required
Ambulatory Care: Disabled (ambc)			NQ	Not Required
Ambulatory Care: Other (ambd)			NQ	Not Required
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)			R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)			NQ	Not Required
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)			NQ	Not Required
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)			NQ	Not Required
Identification of Alcohol and Other Drug Services: Total (iada)	Y		R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	Y		NQ	Not Required
Identification of Alcohol and Other Drug Services: Disabled (iadc)	Y		NQ	Not Required
Identification of Alcohol and Other Drug Services: Other (iadd)	Y		NQ	Not Required
Mental Health Utilization: Total (mpta)	Y		R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	Y		NQ	Not Required
Mental Health Utilization: Disabled (mptc)	Y		NQ	Not Required
Mental Health Utilization: Other (mptd)	Y		NQ	Not Required
Antibiotic Utilization: Total (abxa)	Y		R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Y		NQ	Not Required
Antibiotic Utilization: Disabled (abxc)	Y		NQ	Not Required
Antibiotic Utilization: Other (abxd)	Y		NQ	Not Required
Risk Adjusted Utilization				
Plan All-Cause Readmissions (pcr)			R	Reportable
Health Plan Descriptive				
Board Certification (bcr)			NQ	Not Required
Enrollment by Product Line: Total (enpa)			R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)			NQ	Not Required
Enrollment by Product Line: Disabled (enpc)			NQ	Not Required
Enrollment by Product Line: Other (enpd)			NQ	Not Required
Enrollment by State (ebs)			R	Reportable
Language Diversity of Membership (ldm)			R	Reportable
Race/Ethnicity Diversity of Membership (rdm)			R	Reportable
Total Membership (t1m)			R	Reportable
Measures Collected using Electronic				
Depression Screening and Follow-Up for Adolescents and Adults (dsf)				
Depression Screening: Total Total			NR	Not Reported
Follow-up on Positive Screen: Total Total			NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms)				
Utilization of PHQ-9 - Time period 1: Total Total			NR	Not Reported
Utilization of PHQ-9 - Time period 2: Total Total			NR	Not Reported
Utilization of PHQ-9 - Time period 3: Total Total			NR	Not Reported
Utilization of PHQ-9 - Total: Total Total			NR	Not Reported
Depression and Remission or Response for Adolescents and Adults (drr)				
Follow-up PHQ-9: Total Total			NR	Not Reported
Depression Remission: Total Total			NR	Not Reported
Depression Response: Total Total			NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up (asf)				
Alcohol Use Screening: Total Total			NR	Not Reported
Counseling or Other Follow-up Postive Screen: Total Total			NR	Not Reported
Adult Immunization Status (ais)				
Influenza: Total			NR	Not Reported
Td or Tdap: Total			NR	Not Reported
Zoster: Total			NR	Not Reported
Composite: Total			NR	Not Reported
Prenatal Immunization Status (prs)				
Influenza: Total			NR	Not Reported
Td or Tdap: Total			NR	Not Reported

Combination: Total			NR	Not Reported
--------------------	--	--	----	--------------